Sassine leaves Visiomed
Monday, 07 February, 2005
WA biotech Visiomed (ASX:VSG) has replaced retiring CEO Saliba Sassine with William Dolphin, formerly of New Zealand's SpectraNet and patient monitoring equipment company, SonaMed.
Dolphin, who is to take control in April, will be responsible for moving Visiomed's FDA-cleared asthma device, the Funhaler, into commercial production.
The change is one of several to have occurred at CEO level among Australian biotechs this year.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
